Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

JL Carter, K Hege, J Yang, HA Kalpage, Y Su… - Signal transduction and …, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

ARD Delbridge, S Grabow, A Strasser… - Nature Reviews Cancer, 2016 - nature.com
The'hallmarks of cancer'are generally accepted as a set of genetic and epigenetic
alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows …

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

DA Pollyea, BM Stevens, CL Jones, A Winters, S Pei… - Nature medicine, 2018 - nature.com
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia
stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated …

Cancer drug resistance: an evolving paradigm

C Holohan, S Van Schaeybroeck, DB Longley… - Nature Reviews …, 2013 - nature.com
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …

Nitrogen-containing heterocycles as anticancer agents: An overview

DK Lang, R Kaur, R Arora, B Saini… - Anti-Cancer Agents in …, 2020 - ingentaconnect.com
Background: Cancer is spreading all over the world, and it is becoming the leading cause of
major deaths. Today's most difficult task for every researcher is to invent a new drug that can …

Why do BCL-2 inhibitors work and where should we use them in the clinic?

J Montero, A Letai - Cell Death & Differentiation, 2018 - nature.com
Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …

Venetoclax for AML: changing the treatment paradigm

DA Pollyea, M Amaya, P Strati… - Blood advances, 2019 - ashpublications.org
Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

N Jacque, AM Ronchetti, C Larrue… - Blood, The Journal …, 2015 - ashpublications.org
Cancer cells require glutamine to adapt to increased biosynthetic activity. The limiting step in
intracellular glutamine catabolism involves its conversion to glutamate by glutaminase (GA) …

Targeting mitochondria for cancer therapy

S Fulda, L Galluzzi, G Kroemer - Nature reviews Drug discovery, 2010 - nature.com
Mitochondria are the cells' powerhouse, but also their suicidal weapon store. Dozens of
lethal signal transduction pathways converge on mitochondria to cause the permeabilization …

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

H Inuzuka, S Shaik, I Onoyama, D Gao, A Tseng… - Nature, 2011 - nature.com
The effective use of targeted therapy is highly dependent on the identification of responder
patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is …